64 Chapter 3 17. van der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. J Alzheimers Dis. 2018;62:1091–1111. 18. van der Flier WM, Pijnenburg YA, Prins N, et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. J Alzheimers Dis. 2014;41:313–327. 19. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:270–279. 20. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging- Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7:263–269. 21. Golla SS,Verfaillie SC, Boellaard R, et al.Quantification of [18F] florbetapir: a test–retest tracer kinetic modelling study. J Cereb Blood FlowMetab. 2019;39:2172–2180. 22. Tijms BM, Willemse EA, Zwan MD, et al. Unbiased approach to counteract upward drift in cerebrospinal fluid amyloid-b 1-42 analysis results. Clin Chem. 2018;64:576–585. 23. Seibyl J, Catafau AM, Barthel H, et al. Impact of training method on the robustness of the visual assessment of 18F-florbetaben PET scans: results from a phase-3 study. J NuclMed. 2016;57:900–906. 24. Zwan M, van Harten A, Ossenkoppele R, et al. Concordance between cerebrospinal fluid biomarkers and [11C] PIB PET in a memory clinic cohort. J Alzheimers Dis. 2014;41:801– 807. 25. Golla SS, Timmers T, Ossenkoppele R, et al. Quantification of tau load using [18F] AV1451 PET. Mol Imaging Biol. 2017;19:963–971. 26. Braak H, Braak E. Staging of Alzheimer’s disease-related neurofibrillary changes. Neurobiol Aging. 1995;16:271–278. 27. Schwarz AJ, Yu P, Miller BB, et al. Regional profiles of the candidate tau PET ligand 18F-AV1451 recapitulate key features of Braak histopathological stages. Brain. 2016;139:1539– 1550. 28. Timmers T, Ossenkoppele R, Wolters EE, et al. Associations between quantitative [18F] flortaucipir tau PET and atrophy across the Alzheimer’s disease spectrum. Alzheimers Res Ther. 2019;11:60. 29. Wolters EE, Ossenkoppele R, Verfaillie SC, et al. Regional [18F] flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2020;47:2866–2878. 30. Scholl M, Lockhart SN, Schonhaut DR, et al. PET imaging of tau deposition in the aging human brain. Neuron. 2016;89:971–982. 31. Teo B-K, Seo Y, Bacharach SL, et al. Partial-volume correction in PET: validation of an iterative postreconstruction method with phantom and patient data. J Nucl Med. 2007;48:802– 810. 32. Christian BT, Vandehey NT, Floberg JM, Mistretta CA. Dynamic PET denoising with HYPR processing. J NuclMed. 2010;51:1147–1154.
RkJQdWJsaXNoZXIy MjY0ODMw